Dexcom, a continuous glucose monitoring (CGM) company founded in 1999, continues to battle for the top spot in their industry. While Dexcom was the first company to receive FDA approval for CGM, and CGM continues to provide the company with over $1 billion a year in revenue, they face heavy competition from medical device giants Medtronic and Abbott. Dexcom has always had an aggressive patent prosecution strategy - the company has hundreds of applications to its name, the company has recently shifted to apply AI to their devices, as demonstrated by their portfolio. Since 2017, the company has 12 applications in the AI biotech sector, likely in an effort to stay competitive and on the cutting edge with these larger companies. Will we see their competitors follow suit?
